Produced from used motor oil through Vertex’s integrated collection network, the VTX-R6 supports applications requiring ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2025 Earnings Call Transcript February 12, 2026 Vertex Pharmaceuticals ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) has signed a license and research agreement with WuXi Biologics for a trispecific T cell engager targeting B cell mediated autoimmune diseases. The deal gives ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics (NASDAQ:CRSP) executives highlighted progress across its oncology and autoimmune cell therapy pipeline ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best high growth high margin stocks to buy now. On January 28, Barclays began coverage of Vertex Pharmaceuticals Incorporated ...

CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.

A governance layer (VirtueGov) helps businesses enforce standards, uphold compliance requirements and meet internal policies across AI deployments and agents. The platform also includes tools to ...

FDA vouchers are normally a coveted prize for biopharma companies, but a surprise rejection for Disc Medicine’s rare disease drug has biopharma reconsidering.

Citi's 2026 Virtual Oncology Leadership Summit February 18, 2026 10:45 AM ESTCompany ParticipantsSamarth Kulkarni - CEO ...

ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025.

Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer Jennifer Doudna wants to build an entire ecosystem to bring these treatments ...